PRLD
Prelude Therapeutics Incorporat
$4.86
-5.63%
2026-05-08
About Prelude Therapeutics Incorporat
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing JAK2V617F, a driver mutation product for the treatment of myeloproliferative neoplasms, myelofibrosis (MF), polycythemia vera, and essential thrombocythemia (ET); KAT6A for the treatment of advanced breast cancer and other solid tumors; and mutated calreticulin degrader antibody conjugates to treat MF and ET. The company has collaboration with AbCellera Biologics to discover, develop, and commercialize novel degrader antibody conjugates. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.
Key Fundamentals
Forward P/E
-5.34
EPS (TTM)
$-1.29
ROE
-99.5%
Revenue Growth (YoY)
41.0%
Profit Margin
0.0%
Debt/Equity
25.92
Price/Book
6.16
Beta
1.10
Market Cap
$408.3M
Avg Volume (10D)
640K
Recent Breakout Signals
No recent breakout signals detected for PRLD.
Recent Price Range (60 Days)
60D High
$5.54
60D Low
$2.01
Avg Volume
381K
Latest Close
$4.86
Get breakout alerts for PRLD
Sign up for Breakout Scanner to receive daily notifications when PRLD triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial. No card required.
Prelude Therapeutics Incorporat (PRLD) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors PRLD daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. PRLD operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.